文献速递主动脉疾病内脏/肾动脉与血管畸形

开窗EVAR术后Advanta V12覆膜支架的中期结局

Outcomes of Advanta V12 Covered Stents After Fenestrated Endovascular Aneurysm Repair.
PubMed 文献 · J Endovasc Ther · 2021-05-19

本研究回顾性纳入两个中心194例开窗EVAR患者,共置入457枚Advanta V12球囊扩张覆膜支架桥接内脏动脉,中位随访24.6个月。

要点

  • Advanta V12桥接支架3年支架相关并发症率低(8%),再干预率低(6%)。
  • 术中技术成功率93%,院内死亡率3%,3年患者生存率77%。

核心结论

  • Advanta V12作为开窗EVAR的桥接支架,3年支架相关并发症和再干预率低,但相当比例患者需全因再干预,多与支架无关。

研究设计与样本

  • 回顾性研究,纳入2012年1月至2015年12月两个大容量血管中心的194例开窗EVAR患者,均至少使用1枚Advanta V12覆膜支架。

主要发现

  • 共457条内脏动脉置入Advanta V12支架,中位随访24.6个月(IQR 1.6–49.9)。
  • 3年免于全因再干预率70%(95%CI 61%–78%),33%的全因再干预与桥接支架相关。
  • 457枚支架中24枚出现并发症:III型内漏8枚、显著狭窄4枚、闭塞6枚、支架断裂3枚,3枚为复合并发症。
  • 3年免于支架相关并发症率92%(95%CI 88%–95%),免于支架相关再干预率94%(95%CI 91%–97%)。
  • 院内死亡5例(3%),3年患者生存率77%(95%CI 69%–84%),技术成功率为93%。

临床怎么用

  • 开窗EVAR术中使用Advanta V12桥接内脏动脉中期支架相关并发症和再干预率低,但需警惕较高的全因再干预风险。

局限性

  • 回顾性设计,仅纳入两个中心,随访时间异质性大(IQR 1.6–49.9个月),缺乏与其它桥接支架的对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fenestrated endovascular aneurysm repair (FEVAR) is a well-established endovascular treatment option for pararenal abdominal aortic aneurysms in which balloon-expandable covered stents (BECS) are used to bridge the fenestration to the target vessels. This study presents midterm clinical outcomes and patency rates of the Advanta V12 BECS used as a bridging stent. METHODS: All patients treated with FEVAR with at least 1 Advanta V12 BECS were included from 2 large-volume vascular centers between January 2012 and December 2015. Primary endpoints were freedom from all-cause reintervention, and freedom from BECS-associated complications and reintervention. BECS-associated complications included significant stenosis, occlusion, type 3 endoleak, or stent fracture. Secondary endpoints included all-cause mortality in-hospital and during follow-up. RESULTS: This retrospective study included 194 FEVAR patients with a mean age of 72.2±8.0 years. A total of 457 visceral arteries were stented with an Advanta V12 BECS. Median (interquartile range) follow-up time was 24.6 (1.6, 49.9) months. The FEVAR procedure was technically successful in 93% of the patients. Five patients (3%) died in-hospital. Patient survival was 77% (95% CI 69% to 84%) at 3 years. Freedom from all-cause reintervention was 70% (95% CI 61% to 78%) at 3 years, and 33% of all-cause reinterventions were BECS associated. Complications were seen in 24 of 457 Advanta V12 BECSs: type 3 endoleak in 8 BECSs, significant stenosis in 4 BECSs, occlusion in 6 BECSs, and stent fractures in 3 BECSs. A combination of complications occurred in 3 BECSs: type 3 endoleak and stenosis, stent fracture and stenosis, and stent fracture and occlusion. The freedom from BECS-associated complications for Advanta V12 BECSs was 98% (95% CI 96% to 99%) at 1 year and 92% (95% CI 88% to 95%) at 3 years. The freedom from BECS-associated reinterventions was 98% (95% CI 95% to 100%) at 1 year and 94% (95% CI 91% to 97%) at 3 years. CONCLUSION: The Advanta V12 BECS used as bridging stent in FEVAR showed low complication and reintervention rates at 3 years. A substantial number of FEVAR patients required a reintervention, but most were not BECS related.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. van der Riet C, Schuurmann RCL, Verhoeven ELG, et al. Outcomes of Advanta V12 Covered Stents After Fenestrated Endovascular Aneurysm Repair. J Endovasc Ther. 2021. PMID: 34008441. doi:10.1177/15266028211016423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。